Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould has reiterated an 'Overweight' rating on Gilead Sciences (NASDAQ: GILD) and maintained a price target of $155 for the stock. This endorsement suggests confidence in Gilead's future performance in the market.